Stock Evaluator: Insulet Corporation (PODD)

Insulet Corporation PODD

$145.34 0.05 0.03%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,367,712
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics PODD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $10,083.8 $380.3 78%
Shares Out (Mil) 69.5 41.2 54%
Institutional Ownership 99.7% 84.0% 92%
Float (Mil) 69.1 35.2 53%
Beta 1.05 0.85 63%
Avg Daily Volume (000s) 1,488 341 75%
Price Change
(52-week)
(56.3%) 59.6% 17%
Growth PODD Industry
Median
Percentile
(All Stocks)
Sales (5yr) 24.5% 11.8% 86%
Net Income (5yr) 105.2% (5.6%) 99%
EPS (5yr) 103.4% 10.6% 99
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (18.2%) (16.0%) 38%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 23 25 25
Current EPS $1.753 $6.775 $7.910
Month Ago EPS $1.846 $6.507 $7.722
# Rev Up 0 1 1
# Rev Down 2 0 0
Three Months Ago EPS $1.841 $6.503 $7.711
Year/Year Chg (13.6%) 94.7% 168.1%
Financials PODD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3,189 $127 67%
Net Income (TTM) (Mil) $429 ($9) 76%
EPS (TTM) $6.146 ($0.300) 89%
Operating Cash Flow (TTM) (Mil) $509 ($1) 71%
Net Cash Flow (TTM) (Mil) ($173) $2 11%
Long-Term Debt (Q1) (Mil) $1,019 $25 66%
Enterprise Value (Q1) (Mil) $11,284 $400 76%
Valuation PODD Industry
Median
Percentile
(All Stocks)
P/B 6.39 2.62 86%
P/E 23.7 26.0 62%
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) 0.2 1.3 10%
Ratios PODD Industry
Median
Percentile
(All Stocks)
Gross Margin 71.9% 59.1% 83%
Net Margin 13.4% (4.5%) 70%
ROA 13.3% (11.0%) 91%
ROE 28.9% (8.5%) 87%
Liabilities to Assets 53.8% 45.9% 47%
F-Score 7 4 82%

Insulet Corporation did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors